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REGULATION OF GLUCOSE METABOLISM BY CENTRAL INSULIN ACTION 
Hiroshi Inoue 
Frontier Science Organization, Kanazawa University, Kanazawa, Japan
Insulin has been known to act on the hypothalamus, in particular the arcuate nucleus, in the central nervous system. Such central 
insulin action is not only involved in the regulation of energy metabolism via the regulation of food intake and heat production, 
but also plays an important role in glucose metabolism by regulating hepatic glucose production and glucose uptake by skeletal 
muscles. Studies on the intracerebroventricular administration of PI-3K inhibitors or sulfonylureas have demonstrated that 
hyperpolarization of agouti-related protein neurons induced by the activation of PI-3K signaling/KATP channels in the hypo-
thalamic arcuate nucleus plays an important role in the suppression of hepatic glucose production mediated by central insulin 
action. Cutting of the vagus nerve overrides the suppression of hepatic glucose production by intracerebroventricular insulin 
administration, which suggests the involvement of autonomic nerves in central insulin action in the liver. The central insulin 
action-mediated suppression of hepatic glucose production is associated with decreased gene expression of enzymes involved 
in hepatic gluconeogenesis, and both increased interleukin-6 expression in hepatic non-parenchymal cells induced by central 
insulin action and associated activation of hepatic STAT3 play an important role in the suppression of gene expression of hepatic 
gluconeogenesis-related enzymes. In animal models of obesity and insulin resistance, the central insulin action-mediated he-
patic glucose production control mechanism is impaired in both the hypothalamus and liver. Increased hepatic gluconeogenesis 
in obesity and type-2 diabetes has been attributed to impaired hepatic insulin signaling and increased expression of enzymes 
involved in hepatic gluconeogenesis due to hyperglycemia, but may also be partially attributed to the impairment of the central 
insulin action-mediated suppression of hepatic gluconeogenesis. Biomed Rev 2011; 22: 31-39.
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INTROdUCTION
Homeostasis of energy metabolism is maintained by the close 
interaction between the central nervous system (CNS) and pe-
ripheral tissues. In response to changes such as food intake, a 
stimulus is sent from peripheral tissues to the CNS to regulate 
energy intake, and this is followed by the transmission of a 
command from the CNS to the peripheral tissues to regulate en-
ergy metabolism, such as increasing heat production (1, 2). In 
such CNS-peripheral tissue interactions, a variety of humoral 
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factors play an important role especially in the transmission of 
information from peripheral tissues to the CNS. Previous stud-
ies have demonstrated that factors such as leptin, adiponectin, 
both secreted by adipose tissue, and glucagon like-peptide 1 
secreted by intestinal tissue, play an important role in energy 
metabolism through their action on the CNS (3-5). Insulin, 
a potent regulator of glucose metabolism acting on the liver, 
skeletal muscle, and adipose tissue, has also been shown to 
regulate energy metabolism through its action on the CNS. 
Recent studies have also demonstrated that insulin action on 
the CNS not only regulates energy metabolism via the regula-
tion of food intake and heat production, but is also involved in 
the regulation of glucose metabolism (6,7). These observations 
indicate that insulin regulates glucose metabolism via both the 
direct action on peripheral organs and the indirect regulation 
through its action on the CNS. The purpose of this article is 
to discuss the role of central insulin action in the regulation of 
glucose metabolism, with a focus on its recently-discovered 
action on the regulation of hepatic glucose production.
CENTRAL INSULIN ACTION ANd ENERGY METABOLISM
Studies using 125I-labeled insulin have demonstrated that 
circulating insulin acts on limited areas of the brain such 
as the hypothalamus, in particular the arcuate nucleus, and 
the choroid plexus (8-10). In particular, insulin action in the 
hypothalamic arcuate nucleus, which has both insulin and 
leptin receptors (11), plays an important role in the regula-
tion of energy metabolism (Fig. 1). Brain endothelial cells are 
connected to each other by tight junctions to form the blood-
brain barrier (BBB), which inhibits the entry of molecules 
larger than 400 Da into the CNS (12). Several mechanisms 
of how insulin, a molecule of some 5800 Da, is transported 
into the brain have been reported and include diffusion from 
periventricular regions lacking the BBB, such as the median 
eminence near the arcuate nucleus (13), and the involvement 
of insulin receptor-mediated transport mechanisms in the BBB 
(12). Studies using hyperinsulinemic euglycemic clamps have 
shown that an increase in insulin level in cerebrospinal fluid 
is limited, even in the presence of a significantly high level of 
Figure 1. Central insulin action and energy metabolism. Insulin acts on the hypothalamus, especially the arcuate nucleus. 
Hypothalamic insulin action suppresses food intake, induces glucose uptake in the muscle, decreases hepatic glucose production, 
and increases thermogenesis in brown adipose tissue and lipogenesis in white adipose tissue.
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circulating insulin, indicating the saturation of insulin transport 
into the CNS. These observations suggest the involvement of 
not only simple diffusion, but also carrier-mediated transport 
mechanisms in the saturable transport of insulin into the CNS 
(14-16).
Central insulin action plays an important role in food intake 
regulation. In a study using monkeys, intracerebroventricular 
administration of insulin led to decreases in food intake and 
body weight (17). Rat studies have also demonstrated similar 
effects following the intracerebroventricular administration of 
insulin or low-molecular weight compounds that can activate 
the insulin receptor (1,18). The neuron-specific insulin receptor 
knockout (NIRKO) mouse is an animal model of impaired cen-
tral insulin action (19). The female NIRKO mouse exhibits a 
significant increase in food intake, and both males and females 
increase adipose tissue and body weight and develop insulin 
resistance (19). Such central insulin action-mediated regulation 
of food intake has been attributed to an action on neuropep-
tide tyrosine (NPY)/agouti-related protein (AgRP) neurons, 
which mediate orexigenic effects, and pro-opiomelanocortin 
(POMC)/cocaine-amphetamine-regulated transcript (CART) 
neurons, which mediate the anorexic effects in the hypo-
thalamus. Intracerebroventricular administration of insulin 
leads to decreased expression of NPY and increased expres-
sion of POMC, resulting in suppressed food intake (1,6,20). 
When insulin binds to its receptor, it transmits information 
to cells by activating the phosphoinositide-3-kinase (PI3-K) 
and mitogen-activated protein kinase/extracellular-regulated 
kinase (MAPK) signaling pathways (21). The PI3-K signal-
ing pathway has been shown to play an important role in the 
suppression of food intake mediated by insulin signaling in the 
CNS. Actually, studies have demonstrated that the anorexic 
effect of intracerebroventricular insulin administration can 
be inhibited by intracerebroventricular pretreatment with a 
PI3-K inhibitor (22). Leptin, which acts on the hypothalamus, 
suppresses food intake, and regulates energy metabolism, is 
reported to activate the hypothalamic PI3-K signaling pathway 
(23). Leptin regulates the expression of AgRP and POMC 
through activation of the PI3-K signaling pathway and it also 
regulates the expression of signal transducer and activator of 
transcription-3 (STAT3) signaling (24). STAT3-dependent 
regulation of AgRP and POMC expression is suppressed 
by competitive binding of each transcriptional promoter by 
Forkhead box O1 (FoxO1) (25), which is inhibited by the 
activation of PI3-K signaling (26, 27). Given that insulin does 
not activate hypothalamic STAT3, insulin regulates AgRP and 
POMC expression via inactivation of hypothalamic FoxO1 by 
PI-3K signaling (25,28). Central insulin action also plays an 
important role in increasing heat production following food 
intake via the regulation of sympathetic activity. The dietary 
control of sympathetic activity is critically mediated by insulin 
action in the ventromedial hypothalamus (VMH) (29). This 
finding is supported by the observation that the destruction 
of the VMH by the administration of gold thioglucose leads 
to suppression of heat production following food intake and 
impaired regulation of sympathetic activity (29, 30). Studies 
have suggested the involvement of hypothalamic PI-3K and 
MAPK in the regulation of sympathetic activity mediated by 
central insulin action. In particular, regulation of sympathetic 
stimulation of brown adipocytes, a major source of heat pro-
duction in mice, has been suggested to be critically mediated 
by the activation of hypothalamic MAPK (31).
The involvement of central insulin action has also been 
suggested in the regulation of lipogenesis in white adipose 
tissue (32). A 7-day continuous intracerebroventricular insulin 
administration with an osmotic pump resulted in increased 
adipose tissue weight and increased expression of lipopro-
tein lipase in adipose tissue (32). However, the detailed role 
of central insulin action in white adipose tissue has not been 
elucidated. These observations indicate that insulin plays an 
important role in the homeostasis of energy metabolism by 
decreasing food intake and increasing heat production through 
its action on the hypothalamus.
CENTRAL INSULIN ACTION REGULATES GLUCOSE 
METABOLISM
There is an increasing amount of evidence to suggest that 
central insulin action plays an important role in the regula-
tion of glucose metabolism as well as energy metabolism. 
Obici and colleagues developed rats deficient in hypothalamic 
insulin receptors by intracerebroventricular administration of 
antisense oligonucleotides and found that these rats exhibited 
insulin resistance (33). A study using hyperinsulinemic eug-
lycemic clamps has shown that insulin resistance produced 
by knocking down hypothalamic insulin receptors is not 
associated with impaired glucose uptake in muscles and fat 
tissues but is attributed to impaired suppression of glucose 
production; in other words, increased glucose production in 
the liver (33). The NIRKO mouse, which also exhibits insulin 
resistance, has been shown to exhibit increased hepatic glucose 
production in a hyperinsulinemic euglycemic clamp study (34). 
Another study has demonstrated that the intracerebroventricu-
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lar administration of insulin in rat or mouse models leads to 
suppressed glucose production in the liver (35,36). Central 
insulin action, acting mainly on the hypothalamic arcuate nu-
cleus, has been shown to regulate hepatic glucose production 
via the vagus nerve (33). Cutting of the vagal hepatic branch 
has been demonstrated to result in reduced hepatic glucose 
production following intracerebroventricular administration 
of insulin (36). These studies suggest that the central insulin 
action regulates glucose metabolism through the suppression 
of hepatic glucose production via the vagal nerve. It has been 
reported that central insulin action activates hepatic glycogen 
synthesis (37). Considering that hepatic glycogen synthase is 
known to be activated by hepatic vagal nerve activation (38), 
central insulin action also regulates hepatic glycogen synthesis 
via the vagal nerve.
Hyperinsulinemic euglycemic clamp studies with insulin 
administration at high concentrations are used to examine in 
detail the effect of insulin on glucose uptake by peripheral 
organs, including skeletal muscles (39). A recent study using 
the euglycemic clamp with high-dose insulin administration 
has shown that the inhibition of central insulin action does not 
alter glucose uptake by adipose tissue, but reduces glucose 
uptake by skeletal muscles (40). Increased synthesis of gly-
cogen in skeletal muscles has also been observed following 
intracerebroventricular administration of insulin in mice (41). 
Thus, the central insulin action may also play a certain role in 
glucose metabolism in skeletal muscles.
The PI-3K signaling pathway in the hypothalamic arcuate 
nucleus plays an important role in the regulation of glucose 
metabolism mediated by central insulin action. In rats, the 
intracerebroventricular administration of a PI-3K inhibitor 
to inhibit central insulin action leads to a decrease in insulin-
dependent hypoglycemic response and an increase in glucose 
production in the liver (35,42). The use of an adenovirus vec-
tor to induce overexpression of a constitutively active mutant 
of Akt, which is activated by PI-3K, in the arcuate nucleus 
results in an enhanced hypoglycemic response to insulin with 
no change in food intake (42). These findings suggest that 
activation of the PI-3K signaling pathway in the CNS, espe-
cially in the hypothalamic arcuate nucleus, leads to suppressed 
glucose production in the liver and thus plays a certain role in 
the hypoglycemic response to insulin.
The KATP channels in the hypothalamus have been shown 
to play an important role in the suppression of hepatic glu-
cose production mediated by the central insulin action. The 
intracerebroventricular administration of KATP channel blocker 
sulfonylurea can reverse the suppression of hepatic glucose 
production by central insulin action (35). Insulin has been 
shown to induce hyperpolarization of hypothalamic neurons 
by opening KATP channels via PI-3K (43). This is further sup-
ported by the fact that insulin opens KATP channels in both 
AgRP and POMC neurons and induces hyperpolarization 
of these neurons (44,45). It has also been demonstrated that 
MAPK inhibitors do not affect insulin-induced, hypothalamic 
KATP channel-dependent hyperpolarization (43). AgRP neu-
ron-specific insulin receptor-deficient mice exhibited increased 
hepatic glucose production, whereas in POMC neuron-specific 
insulin receptor-deficient mice, insulin successfully suppressed 
glucose production in the liver (45). These results suggest that 
hyperpolarization and inactivation of AgRP neurons, resulting 
from the activation of PI-3K/KATP channels, play an important 
role in the suppression of hepatic glucose production mediated 
by the central insulin action.
The involvement of central insulin action has also been sug-
gested in the regulation of glucose uptake by skeletal muscles, 
but its mechanism has been unclear (40). Leptin, which also acts 
on KATP channels in the hypothalamus (43), has been shown 
to increase glucose uptake by skeletal muscles by activating 
5’-AMP-activated protein kinase (AMPK) via the sympathetic 
nervous system (46), and the hypothalamic administration of 
leptin has been shown to increase glucose uptake by adipose tis-
sue (47). Intracerebroventricular administration of sulfonylurea 
in a euglycemic clamp study with a high-concentration insulin 
infusion resulted in increased hepatic glucose production and 
reduced glucose uptake by skeletal muscles due to blockage of 
central insulin action by KATP channel blockade (40). At the 
same time, no change in glucose uptake was observed in adipose 
tissue or the heart, and no significant change in AMPK activity 
was observed in skeletal muscles (40). These results suggest the 
regulation of glucose metabolism in skeletal muscles mediated 
by central insulin action has different mechanisms than the 
regulation of glucose metabolism in skeletal muscles mediated 
by central leptin action.
As it becomes increasingly clear how the central insulin 
action regulates hepatic glucose metabolism, studies have 
suggested that the contribution of this mechanism varies de-
pending on the type of animal model. A dog model has been 
developed where insulin is infused from the carotid or vertebral 
artery to selectively increase the level of insulin circulating 
in the head compared with the peripheral insulin level (48). 
This model, where the insulin level in the head was selectively 
increased to a level 4 times higher than that achieved by the 
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standard hyperinsulinemic euglycemic clamp, demonstrated 
the same level of suppression of hepatic glucose production 
as the standard hyperinsulinemic euglycemic clamp. This 
finding indicates that the central insulin action may exert a 
milder suppressive effect on hepatic glucose production in 
dogs than in mice and rats.
MEChANISM OF CENTRAL INSULIN ACTION-MEdIATEd 
REGULATION OF hEpATIC GLUCOSE pROdUCTION
Hepatic glucose production is composed of glycogenolysis and 
gluconeogenesis. Central insulin action-mediated suppression 
of hepatic glucose production has been attributed primarily 
to a decrease in gluconeogenesis (36). Hepatic gluconeo-
genesis is strongly regulated by the expression of the genes 
of related metabolic enzymes, and the central insulin action 
suppresses gene expression of enzymes involved in hepatic 
gluconeogenesis, such as phosphoenolpyruvate carboxykin-
ase and glucose-6-phosphatase. Gene expression of hepatic 
gluconeogenic enzymes is regulated by a number of transcrip-
tion factors, including cyclic-AMP response element binding 
protein (CREB) and FoxO1 (49). Insulin decreases the gene 
expression of hepatic gluconeogenic enzymes by the inhibi-
tion of transcriptional activity of CREB and FoxO1 (50-53). 
Central insulin action also suppresses hepatic gluconeogenic 
gene expression as described above, and hepatic STAT3 plays 
an important role as a transcription factor involved in this 
suppression by central insulin action (34). Hepatic STAT3 sup-
presses gene expression of enzymes involved in hepatic glu-
coneogenesis when activated by interleukin-6 (IL-6) (54,55). 
This is further supported by liver-specific STAT3-deficient 
mice that develop insulin resistance as the gene expression of 
hepatic gluconeogenic enzymes increases, leading to glucose 
intolerance under the condition of obesity induced by high-
fat diet feeding (54). Activation of hepatic STAT3 induced 
by the central insulin action has been demonstrated to be due 
to increased secretion of IL-6 from hepatic non-parenchymal 
cells (34). However, the role of the vagus nerve in hepatic 
STAT3 activation by central insulin action has not been fully 
elucidated. These observations indicate that insulin inhibits 
the expression of hepatic gluconeogenic genes by the direct 
action on the hepatocyte inhibiting CREB and FoxO1 activity 
and by central insulin action activating hepatic STAT3 (Fig. 2).
Figure 2. Direct and indirect regulation of hepatic gluconeogenic gene expression by insulin. Insulin inhibits the transcriptional 
activity of FoxO1 and CREB and suppresses hepatic gluconeogenesis in a PI3-K signaling-dependent manner in hepatocytes. In 
addition to the direct effect on hepatocytes, central insulin action increases IL-6 expression in non-parenchymal hepatic cells, 
which activates hepatic STAT3 in a paracrine manner and decreases expression of hepatic gluconeogenic enzyme genes.
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Species difference has been suggested regarding the cen-
tral insulin action-mediated suppression of hepatic glucose 
production, as evidenced by the lack of such suppressive 
mechanisms in dogs (37, 48). However, the central insulin 
action-mediated activation of hepatic STAT3 has been shown 
to be preserved in dogs as well as in mice (37, 56). This sug-
gests that the contribution of hepatic STAT3 to the regulation 
of gene/protein expression of hepatic gluconeogenic enzymes 
varies among species.
CENTRAL INSULIN ACTION-MEdIATEd REGULATION OF 
hEpATIC GLUCOSE pROdUCTION ANd TYpE 2 dIABETES
Increased hepatic gluconeogenesis has been observed in 
obese individuals with type-2 diabetes (57). The question 
then arises as to the role of the central insulin action-mediated 
suppression of hepatic gluconeogenesis in the presence of 
obesity and insulin resistance. In a rat study, maintaining 
a high level of peripheral blood insulin did not lead to a 
substantial increase in central insulin action, probably due 
to saturation of the transport mechanisms (1). This suggests 
that an increased blood insulin level associated with insulin 
resistance does not lead to a substantial increase in insulin 
action in the CNS. With regard to insulin action in the 
hypothalamus, a study using obese Zucker rats with leptin 
receptor abnormalities has demonstrated that insulin fails to 
induce hyperpolarization of hypothalamic neurons in these 
rats (43). It has also been demonstrated that the intake of 
obesity-inducing high-fat diets, even short-term intake, in-
duces activation of S6 kinase in the hypothalamus and thereby 
inhibits insulin signaling (58). A study using db/db leptin 
receptor-deficient obese mice has shown that the activation 
of hepatic STAT3, an effector of the central insulin action, 
is inhibited by endoplasmic reticulum stress associated with 
insulin resistance in obesity (59). This is further supported 
by the reversal of both the central insulin action-mediated 
suppression of glucose production in the liver and the pro-
motion of glucose uptake by skeletal muscles in obesity 
model mice bred with a high-fat diet (40). Increased hepatic 
gluconeogenesis in type-2 diabetes has been attributed to 
impaired suppression of hepatic glucose production due to 
impaired hepatic insulin signaling and increased expression 
of enzymes involved in hepatic gluconeogenesis due to 
increased activity of CREB associated with hyperglycemia 
(60), but may also be partially attributed to the impairment 
of the central insulin action-mediated suppression of hepatic 
gluconeogenesis.
CONCLUSION
Studies have demonstrated that the central insulin action 
regulates not only food intake and energy metabolism, but 
also glucose metabolism via the regulation of hepatic glucose 
production. Hepatic glucose production plays a key role in 
glucose metabolism, as evidenced by the observation that in-
creased hepatic glucose production leads to impaired glucose 
tolerance (61). Thus, hepatic glucose production is controlled 
by insulin’s direct action on the liver and indirectly via its 
action on the CNS. The fact that various animal models of 
impaired hepatic insulin signaling exhibit profound glucose 
intolerance indicates that the direct action of insulin on the 
liver plays a central role in the homeostasis of glucose me-
tabolism. At the same time, insulin resistance exhibited by 
CNS insulin receptor-deficient mice (19) and liver-specific 
STAT3-deficient mice (50) suggests a role of the central insulin 
action-mediated regulation of hepatic glucose production in 
glucose metabolism.
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